Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This research study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see the
following:
- how effective this combination of study drugs will be in treating HCC
- how long subjects respond to these study drugs
- what types of side effects can be expected, and
- how severe the side effects are
All subjects in this study will receive:
- Sorafenib twice a day by mouth
- Capecitabine twice a day by mouth
Treatment will be given in a 28-day treatment cycle.
Subjects will take sorafenib every day of the cycle. Subjects will take capecitabine on days
1-7 and 15-21 of the cycle